메뉴 건너뛰기
PharmacoEconomics
Volumn 29, Issue 4, 2011, Pages 287-296
Sample size and power for cost-effectiveness analysis (Part 2): The effect of maximum willingness to pay
Author keywords

Clinical trial design; Cost effectiveness; Statistics
Indexed keywords

ARTICLE; CALCULATION; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS;
EID: 79952681381     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11585080-000000000-00000     Document Type: Article
Times cited : (13)
References (7)
  • 1
    • 79951643200 scopus 로고    scopus 로고
    • Sample size and power for cost-effectiveness analysis (part 1)
    • Epub 2011 Jan 27
    • Glick HA. Sample size and power for cost-effectiveness analysis (part 1). Pharmacoeconomics. Epub 2011 Jan 27
    • Pharmacoeconomics.
    • Glick, H.A.1
  • 2
    • 0041807885 scopus 로고    scopus 로고
    • What is the price of life and why doesn't it increase at the rate of inflation?
    • DOI 10.1001/archinte.163.14.1637
    • Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate ofinflation? Arch Intern Med 2003 Jul 28; 163 (14): 1637-41 (Pubitemid 36898950)
    • (2003) Archives of Internal Medicine , vol.163 , Issue.14 , pp. 1637-1641
    • Ubel, P.A.1    Hirth, R.A.2    Chernew, M.E.3    Fendrick, A.M.4
  • 3
    • 2442717630 scopus 로고    scopus 로고
    • Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis
    • DOI 10.1002/hec.864
    • Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-52 (Pubitemid 38660393)
    • (2004) Health Economics , vol.13 , Issue.5 , pp. 437-452
    • Devlin, N.1    Parkin, D.2
  • 4
    • 6344260475 scopus 로고    scopus 로고
    • Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?
    • DOI 10.1111/j.1524-4733.2004.75003.x
    • Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28 (Pubitemid 39390832)
    • (2004) Value in Health , vol.7 , Issue.5 , pp. 518-528
    • Eichler, H.-G.1    Kong, S.X.2    Gerth, W.C.3    Mavros, P.4    Jonsson, B.5
  • 5
    • 70349301818 scopus 로고    scopus 로고
    • Life in the balance
    • Cressy D. Life in the balance. Nature 2009; 461: 336-9
    • (2009) Nature , vol.461 , pp. 336-9
    • Cressy, D.1
  • 6
    • 67349270247 scopus 로고    scopus 로고
    • Bevacizumab in combination with paclitaxel for HER-2 nega-tive metastatic breast cancer: An economic evaluation
    • Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 nega-tive metastatic breast cancer: an economic evaluation. Eur J Cancer 2009; 45: 1397-406
    • (2009) Eur J Cancer , vol.45 , pp. 1397-406
    • Dedes, K.J.1    Matter-Walstra, K.2    Schwenkglenks, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.